Sign inJoin waitlistJoin the waitlist

Amanda Strobel

Fellowship Director · University of Mississippi School of Medicine

Credentials: · · · · ·

History

University of Mississippi School of Medicine Fellowship
Present
University of Mississippi School of Medicine
Present
University of Mississippi School of Medicine
Present

Pediatric Hematology-Oncology
2014–2015
Pediatrics
University of Mississippi Medical Center
2011–2014
University of Mississippi School of Medicine
2007–2011

Research

Blastic plasmacytoid dendritic cell neoplasm in an adolescent female: a rare entity with challenging diagnosis and management
Case report · BMJ Case Reports · 2023 · Last of 4 authors · Corresponding
Capillary Leak syndrome within an hour of G-CSF
The Journal of Pediatric Pharmacology and Therapeutics · 2023

AP
Aashima Pandhi
1 paper · 1 as a fellow
Ankit Agarwal
1 paper · 1 as a fellow
Janesha Thomas
1 paper
Joanna Chaffin
1 paper
Michelle Amit
1 paper · 1 as a fellow
Pallavi Agarwal
1 paper

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031